Novo Nordisk veteran Doustdar took charge of the drugmaker in late July, after his predecessor was pushed out with the company losing ground in the anti-obesity drug market. Doustdar has more than 30 years of service at Novo Nordisk and headed the company's international operations before taking on the top job. He said Wednesday that the company would be making further moves to boost focus, performance and decision-making as well as cost savings. "We need a shift in our mindset and approach so we can be faster and more agile. Our transformation plan is designed to deliver this." The company's shares plunged as much as 30% in a single day in late July, at one point wiping out almost $93 billion of its market capitalization, after the drugmaker cut sales and earnings expectations for the year due to headwinds for blockbuster drugs Ozempic and Wegovy. Sales of the drugs have been hurt by the availability of cheaper copycat versions sold in the U.S., a practice known as compounding.